LakeShore Biopharma Completes Going Private Transaction, Ceases Public Trading

LakeShore Biopharma Co., Ltd, a global biopharmaceutical company focused on vaccines and therapeutic biologics for infectious diseases and cancer, announced today the completion of its going private transaction. The merger with Oceanpine Merger Sub Inc., a wholly owned subsidiary of Oceanpine Skyline Inc., was finalized on June 24, 2026, marking the end of the company’s status as a publicly traded entity.

Under the terms of the merger agreement, which was approved by shareholders at an extraordinary general meeting on June 19, 2026, each ordinary share of LakeShore Biopharma was canceled and converted into the right to receive $0.066 in cash, net of applicable withholding taxes. Shareholders entitled to the merger consideration will receive instructions from the paying agent on how to surrender their shares for payment.

The company plans to suspend its reporting obligations under the Securities Exchange Act of 1934 by filing a Form 15 with the U.S. Securities and Exchange Commission (SEC). This will effectively halt the company’s requirement to file reports such as Form 20-F and Form 6-K, with obligations ceasing once deregistration becomes effective. Additionally, the company has filed with the Financial Industry Regulatory Authority (FINRA) to remove its trading symbols from the OTC Pink tier of the OTC Markets. However, removal may take several trading days, and the company warns that any trades executed after the merger’s completion but before removal will be invalid, as the underlying securities no longer exist.

The decision to go private comes after a period of strategic evaluation, with a special committee of independent directors formed to assess the proposal. Kroll, LLC served as financial advisor to the special committee, with Gibson, Dunn & Crutcher LLP and Maples and Calder (Hong Kong) LLP providing legal counsel. White & Case LLP represented the buyer group.

This move has significant implications for LakeShore Biopharma and its shareholders. By going private, the company can focus on long-term strategic goals without the quarterly earnings pressures and regulatory burdens of being a public company. For investors, the transaction provides a clear exit at a fixed price, but also ends any potential for future gains from public trading. The company’s stock, previously listed on the OTC markets under symbols LSBCF and LSBWF, will cease trading, and shareholders must follow the surrender process to receive payment.

LakeShore Biopharma, formerly known as YS Biopharma, has developed a proprietary PIKA immunomodulating technology platform and a range of preventive and therapeutic biologics targeting rabies, hepatitis B, influenza, and other viral infections. The company operates in China, Singapore, and the Philippines. For more information about the company, visit https://investors.lakeshorebio.com/.

The completion of this transaction underscores a trend of biopharmaceutical companies opting for private ownership to streamline operations and focus on research and development away from the public eye. As LakeShore Biopharma transitions to a private entity, it remains to be seen how this change will impact its pipeline and future partnerships.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is LakeShore Biopharma Completes Going Private Transaction, Ceases Public Trading.

The post LakeShore Biopharma Completes Going Private Transaction, Ceases Public Trading appeared first on citybuzz.